About B Capital Group
Mirae Asset is a leading global diversified financial services firm operating out of 30 offices across America, Asia, Europe and the Pacific. Founded in 1997, the company manages over $563bn (as of March 2021) in investor capital across its asset management, investment banking, life insurance and venture capital businesses. Since its founding, the firm has focused on investing in innovative and breakthrough ideas and teams across all sectors.
Leveraging global resources and exclusive partnership with The Boston Consulting Group, B Capital Group is a global investor dedicated to empowering portfolio companies. Our key areas of focus include Enterprise technology, Healthcare, Industrial and Transportation, and Fintech and Insurtech. Our unique partnership with BCG gives our portfolio companies access to a vast network of global resources and empowers them to scale their businesses. We invest in firms at different stages—from venture and growth stage to late stage, to provide them support along their journeys. We have built a global presence with offices in Los Angeles, San Francisco, New York, Singapore, Hong Kong and Beijing. Our portfolio in healthcare sector includes Atomwise (developer of AI technology for drug discovery), Evidation Health (health data analytics platform), and Notable Labs (precision medicine platform), etc. For more information, visit http://www.bcapgroup.com/.
For more information, please visit the HiFiBiO news page here.
With the new round, Ryan Jeong from Mirae Asset Capital will be joining the company’s Board of Directors. “Mirae Asset strives to invest in breakthrough ideas and innovative teams in the life science industry,” said Ryan. “Based on their most recent successful partnerships and demonstrated ability to rapidly advance a sustainable pipeline of innovative therapeutics, we are excited to support HiFiBiO Therapeutics as they pioneer the way immunotherapies are developed and delivered to each and every patient.”
About Mirae Asset Financial Group
“Since the close of our last round, the company has achieved significant milestones, including the rapid development of HFB30132A1, a SARS-CoV-2 neutralizing antibody into Phase I trial (NCT04590430) and the successful launch of IND-enabling studies and biomanufacturing activities for antibodies against multiple novel immuno-oncology targets,” said Liang Schweizer, PhD, President and CEO of HiFiBiO Therapeutics. “In addition, we remain fully committed to the advancement of our pioneering DIS™ approach for identifying disease relevant targets, high quality antibody therapeutics, as well as to validate our biomarker hypothesis in the clinical setting. We appreciate the backing from investor communities around the world who resonate with our vision to take this powerful drug discovery and development engine to the next level.”
Established in 2004, Maison Capital is a leading Chinese private equity firm currently managing both RMB and USD funds with offices in Shenzhen, Beijing and Hong Kong. It focuses on growth stage investments in consumer lifestyle, consumer technology and consumer healthcare companies with China-related businesses. Maison Capital makes long-term and independent investment decisions empowered by effective and comprehensive bottom-up research. As an early adopter of international ESG standards among Chinese funds, Maison Capital is committed to incorporating ESG principles in its investment processes and businesses it invests in.
About Trinity Innovation Fund
About Maison Capital
Sherpa Healthcare Partners (“Sherpa”) was founded in 2018. The founders of Sherpa previously worked together in one of China’s leading venture capital firms, where they built the dedicated healthcare investment fund and led its professional medical investment team since 2011. The founders have closely cooperated to form a team, built on shared values, mutual trust, and complementary capabilities. Sherpa has now become an influential healthcare VC firm in the industry. Sherpa has invested in leading companies in many key areas, such as Pharma, GeneTech, MedTech and Medical services. From 2011 to 2020, the team has gone through 4 vintage year cycles of multiple U.S dollar funds and RMB funds and made over 100 investments. Sherpa has the honor to work with many outstanding entrepreneurs and grow together with them.
About Sherpa Healthcare Partners
The News Highlights
- HiFiBiO Therapeutics closes $75 million Series D funding to accelerate pipeline with two leading immuno-oncology programs and validate its DIS™ approach in the clinic
- Check the latest News news updates and information about business, finance and more.
For Latest News Follow us on Google News
- Show all
- Trending News
- Popular By week